Advertisement

A coordination model for enhancing research on rare diseases

  • Michela Chessa
  • Vito FragnelliEmail author
  • Stefano Gagliardo
Part of the International Series in Operations Research & Management Science book series (ISOR, volume 173)

Abstract

Rare diseases affect a great number of patients that suffer of the non existence of effective cures. Medical products for prevention, diagnosis or treatment of this kind of disorders are called orphan drugs and pharmaceutical industries have not a great interest under normal market conditions in developing and marketing products for a small number of patients. The Orphan Drug Act and the Regulation on Orphan Medicinal Products played a relevant role in encouraging the development of new orphan drugs, as in America as in Europe. In this chapter we propose that pharmaceutical industries coordinate their researches in order to avoid that two or more of them study a new molecule for the same disease, with the aim of further enhancing the research on rare diseases.

Keywords

rare disease orphan drug multiple knapsack problem college admissions problem 

References

  1. 1.
    Centro Nazionale Malattie Rare (National Center for Rare Diseases). http://www.iss.it/cnmr/. Accessed 28 May 2011Google Scholar
  2. 2.
    DiMasi, J.A., Hansen, R.W., Grabowski, H.G.: The Price of Innovation: New Estimates of Drug Development Costs. J. of Health Econ. 22, 151–185 (2003)CrossRefGoogle Scholar
  3. 3.
    European Medicines Agency. http://www.ema.europa.eu/. Accessed 26 May 2011Google Scholar
  4. 4.
    European Parliament and Council: Regulation (EC) NO 141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products. Off. J. of the Eur. Communities 43, 1–5 (2000)Google Scholar
  5. 5.
    Eurordis — Rare Diseases Europe. http://www.eurordis.org/. Accessed 30 May 2011Google Scholar
  6. 6.
    Gale, D., Shapley, L.S.: College Admissions and the Stability of Marriage. The Am. Math. Mon. 69, 9–15 (1962)CrossRefGoogle Scholar
  7. 7.
    Gites, B., Chughtai, M., Chang, J., Philips, I.M.: Benefits of the Orphan Drug Act for Rare Disease Treatments. TuftScope. http://s3.amazonaws.com/tuftscope exclusives/documents/10/Express Online Spring 2010 Gites.pdf (2010). Accessed 25 May 2011Google Scholar
  8. 8.
    Grabowski, H.: Increasing R&D Incentives for Neglected Diseases — Lessons from the Orphan Drug Act. In: International Public Goods, and Transfer of Technology under a globalized Intellectual Property Regime, pp. 457–480. Cambridge University Press, Cambridge (2005)CrossRefGoogle Scholar
  9. 9.
    Heemstra, H.E., de Vrueh, R.L.A., van Weely, S., Büller, H.A., Leufkens, H.G.M.: Orphan drug development across Europe: bottlenecks and opportunities. Drug Discov. Today 13, 670–676 (2008)CrossRefGoogle Scholar
  10. 10.
    Love, J.: Evidence Regarding Research and Development Investments in Innovative and Non-Innovative Medicines. Consumer Project on Technology, Washington, DC. http://www.cptech.org/ip/health/rnd/evidenceregardingrnd.pdf (2003). Accessed 24 May 2011Google Scholar
  11. 11.
    Martello, S., Toth, P.: Knapsack Problems: Algorithms and Computer Implementations. John Wiley and Sons, New York (1990)Google Scholar
  12. 12.
    Orphan Europe. http://www.orphan-europe.com/. Accessed 27 May 2011Google Scholar
  13. 13.
    Papadimitriou, C.H., Steiglitz, K.: Combinatorial Optimization: Algorithms and Complexity. Prentice-Hall, New Jersey (1982)Google Scholar
  14. 14.
    Roth, A.E., Sotomayor, M.: The College Admissions Problem Revisited. Econometrica 57, 559–570 (1989)CrossRefGoogle Scholar
  15. 15.
    Senate andHouse of Representatives of theUnited States ofAmerica: OrphanDrugAct. Public Law 97–414, 97th Congress (1983)Google Scholar
  16. 16.
    Senate and House of Representatives of the United States of America: Rare Diseases Act of 2002. Public Law 107–280, 107th Congress (2002)Google Scholar

Copyright information

© Springer-Verlag Italia 2012

Authors and Affiliations

  • Michela Chessa
    • 1
  • Vito Fragnelli
    • 2
    Email author
  • Stefano Gagliardo
    • 3
  1. 1.Department of MathematicsUniversity of MilanoMilanoItaly
  2. 2.Department of Sciences and Technological InnovationUniversity of Eastern PiedmontAlessandriaItaly
  3. 3.Department of MathematicsUniversity of GenovaGenovaItaly

Personalised recommendations